Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Neoplasms benign, malignant and unspecified (incl cysts and polyps) – page 256

  • 3 898 clinical trials
  • 1 548 recruiting
  • 703 conditions
  • 31 countries

Conditions in this area

703 conditions with trials, the busiest first

Non-small cell lung cancer327Breast cancer168Plasma cell myeloma164Neoplasm158Acute myeloid leukaemia132Neoplasm malignant129Colorectal cancer metastatic105Prostate cancer101Ovarian cancer91Colorectal cancer89Hepatocellular carcinoma89Breast cancer metastatic84Non-small cell lung cancer metastatic82Malignant melanoma79Chronic lymphocytic leukaemia77Triple negative breast cancer69Squamous cell carcinoma of head and neck68Hormone receptor positive HER2 negative breast cancer62Non-small cell lung cancer stage IV57Pancreatic carcinoma57Hormone-refractory prostate cancer56Gastric cancer55Bladder cancer54Endometrial cancer53+679

Clinical trials in Neoplasms benign, malignant and unspecified (incl cysts and polyps)

3 898 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

3 898 clinical trials

Adenocarcinoma gastric+1

Not recruiting

Study of Pembrolizumab with Chemotherapy for Patients with Advanced Gastric or Gastroesophageal Junction Cancer

Registered drug
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Merck Sharp & Dohme LLC

Plasma cell myeloma refractory

Not recruiting

Study on Isatuximab, Carfilzomib, and Dexamethasone for Adults with Relapsed or Refractory Multiple Myeloma

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Carfilzomib
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Soft tissue sarcoma

Not recruiting

Study on the Effectiveness and Safety of L19TNF and Dacarbazine for Patients with Advanced or Metastatic Soft-Tissue Sarcoma After Previous Treatments

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Dacarbazine
  • Sponsor:Philogen S.p.A.

Neoplasm

Not recruiting

Study on the Safety and Effectiveness of MK-1200 for Patients with Advanced Solid Tumors

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Mk-1200
  • Sponsor:Merck Sharp & Dohme LLC

Dedifferentiated liposarcoma

Not recruiting

Study on the Safety and Tolerance of BI 907828 in Patients with Advanced Dedifferentiated Liposarcoma

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:(3S,3'S,3A's,10A's)-6-Chloro-3'-(3-Chloro-2-Fluorophenyl)-1'-(Cyclopropylmethyl)-6'-Methyl-2-Oxo-1,2,3',3A',10',10A'-Hexahydro-1'H-Spiro[Indole-3,2'-Pyrrolo[2',3':4,5]Pyrrolo[1,2-B]Indazole]-7'-Carboxylic Acid
  • Sponsor:Boehringer Ingelheim International GmbH

Leukaemia+1

Not recruiting

Study of dasatinib treatment in children and adolescents with Philadelphia chromosome-positive leukemia who cannot take imatinib or for whom imatinib is not effective

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:0–17 years
  • Substances:Dasatinib
  • Sponsor:Bristol Myers Squibb International Corporation

Bladder transitional cell carcinoma

Not recruiting

Study on TAR-200 and Cetrelimab for Patients with Muscle-Invasive Bladder Cancer Ineligible for or Refusing Platinum-Based Chemotherapy

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Cetrelimab
  • Sponsor:Janssen Cilag International

Soft tissue sarcoma

Not recruiting

Study on L19TNF and Doxorubicin for Patients with Advanced or Metastatic Soft Tissue Sarcoma

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Onfekafusp Alfa
  • Sponsor:Philogen S.p.A.

Biliary neoplasm+1

Not recruiting

Study on Rilvegostomig and Chemotherapy for Patients with Biliary Tract Cancer After Surgery

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:AstraZeneca AB

Adenocarcinoma gastric+1

Not recruiting

Study of Zolbetuximab Alone and with Drug Combination for Patients with Advanced Stomach or Gastroesophageal Junction Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Fluorouracil
  • Sponsor:Astellas Pharma Global Development Inc.

Non-small cell lung cancer

Not recruiting

Study on the Safety and Effectiveness of Amivantamab and Capmatinib for Patients with Unresectable Metastatic Non-Small Cell Lung Cancer

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Amivantamab
  • Sponsor:Janssen Cilag International

Thyroid cancer+18

Not recruiting

Study of JK08, Pembrolizumab, and Lenvatinib for Patients with Advanced or Metastatic Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Lenvatinib
  • Sponsor:Salubris Biotherapeutics Inc.

Substances studied in this area

The therapies tested most often in Neoplasms benign, malignant and unspecified (incl cysts and polyps) trials.

Pembrolizumab462 clinical trialsCarboplatin340 clinical trialsCisplatin285 clinical trialsPaclitaxel263 clinical trialsFluorouracil237 clinical trialsOxaliplatin227 clinical trialsNivolumab217 clinical trialsDexamethasone169 clinical trialsBevacizumab163 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.